Paolo Tarantino, Advanced research fellow at Dana-Farber Cancer Institute, shared a post on X:
“2025 is anticipated to be the year with the highest number of phase 3 ADC trials read outs in breast oncology, with impact for all breast cancer subtypes.
Here’s 8 ADC breast cancer trials expected to reshape practice in 2025.”
